Hilar cholangiocarcinoma

Disease Description (Causes and Symptoms)

• Definition: Hilar cholangiocarcinoma (Klatskin tumor) is a bile duct cancer that develops in the hepatic hilum (hilar bile duct confluence), where the left and right intrahepatic bile ducts meet. It primarily presents clinically with jaundice caused by obstruction of bile drainage.
• Pathophysiology: Bile stasis occurs due to bile duct stricture at the hepatic hilum, with elevations in bilirubin, alkaline phosphatase (ALP), and gamma-GT, as well as the possibility of liver injury and infection (cholangitis) due to cholestasis. If the tumor extends into surrounding blood vessels or the liver parenchyma, resection becomes difficult. The Bismuth–Corlette classification (the extent of the tumor's involvement of the left and right intrahepatic bile ducts) is important for surgical planning.
• Major causes and risk factors: Cholelithiasis, clonorchiasis (liver fluke infection), choledochal cyst (bile duct cyst), primary sclerosing cholangitis (PSC), ulcerative colitis (PSC-associated), congenital hepatic fibrosis, chronic typhoid carrier state, and others. The cause is unknown in many cases.
• Common symptoms: Progressive painless jaundice (dark urine, gray stools), generalized itching, weight loss, loss of appetite, fatigue and anemia, fever and chills (in cases of cholangitis), and abdominal pain (reported by 30–50%).

Treatment Methods

• Diagnostic evaluation and preparation
  • Blood tests: Bilirubin, ALP, GGT, liver function tests, and tumor markers (CEA and CA 19-9 for reference).
  • Imaging tests: Ultrasound → abdominal CT (assessment of portal vein and liver involvement) → MRI/MRCP (identification of the location and extent of bile duct obstruction).
  • Tissue examination (biopsy) and stent placement may be performed through endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic biliary drainage (PTBD).
• Curative treatment
  • Surgical resection: When possible, the goal is curative resection through resection of the hepatic hilum and surrounding liver, including lobectomy. The extent of resection is determined according to the Bismuth classification, vascular involvement, and liver function.
  • Liver transplantation: May be considered in some selected cases, but the criteria are strict, including disease stage and presence or absence of metastasis.
• Biliary drainage (priority treatment)
  • Endoscopic or percutaneous drainage (stent placement) can improve jaundice and cholangitis and promote recovery of liver function before surgery.
• Nonsurgical and conservative treatment
  • Systemic chemotherapy (when surgery is not possible, as adjuvant therapy, or for palliative treatment), and radiation therapy (selective or adjuvant).
  • Local treatments (such as transarterial chemoembolization, applied experimentally or as adjunctive treatment) and palliative care (maintaining biliary drainage and managing pain and itching).
• Symptom and lifestyle management
  • Itching: Adsorbents such as cholestyramine may be used.
  • Nutritional management: Nutritional supplementation (a high-calorie, high-protein diet) in cases of weight loss or nutritional imbalance; referral to a nutrition team if necessary.
  • Medication and lifestyle precautions: Avoid hepatotoxic medications and excessive alcohol. Visit a medical institution immediately in case of infection.
• Prognosis
  • The 5-year survival rate after curative resection, including liver resection, is approximately 10–38%.
  • If left untreated, the average survival period is several months. When only biliary drainage is maintained, survival is usually less than 10 months.
  • Even in patients who cannot undergo surgery, survival may be improved through chemotherapy and local treatment.

Checklist Before an Outpatient Visit (Including Example Questions)

• Items to prepare (recommended to bring to the outpatient visit)
  • A list of currently taken medications, including prescription drugs, nonprescription drugs, and supplements
  • Information on past medical history, surgical records, and allergies
  • Copies or a CD of recent test results, including blood tests, ultrasound, CT/MRI, ERCP/cholangiography, and pathology reports
  • Symptom diary: when jaundice began, changes in urine and stool color, severity of itching, weight changes (recent weight in kg), and frequency of fever and abdominal pain
• Precautions before the outpatient visit
  • Follow fasting instructions when scheduling a test such as ERCP, according to the medical institution's instructions.
  • Inform the medical staff in advance whether you are taking anticoagulants or antiplatelet drugs, and confirm whether they need to be discontinued before the procedure.
• Information to show the doctor during the visit (including example questions)
  • Provide recent imaging and test results along with a diary of symptom changes.
  • Report the status of current medications and treatments, such as stents and drainage tubes.

Examples of General Questions to Ask the Doctor

• "What is the location of my lesion and its Bismuth–Corlette type? Is it resectable?"
• "What treatment sequence do you recommend, such as biliary drainage → surgery → adjuvant chemotherapy?"
• "What is the expected prognosis in my case, including the 5-year survival rate and life expectancy?"
• "What are the major complications of the surgery or procedure, and how long is the recovery period expected to be?"
• "If I am currently taking any medications or supplements, do I need to stop them?"

Examples of Disease-Specific Questions

• "In my imaging results, how extensively has the hilar cholangiocarcinoma invaded the left and right hepatic ducts (specifically, what is the Bismuth classification)?"
• "If curative surgical resection is not possible, what chemotherapy or palliative procedures would you recommend? Can you evaluate whether I meet the indications for liver transplantation?"